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Summary. ACE inhibitors have been shown to be effective
in reducing the morbidity and mortality of patients with left
ventricular systolic dysfunction, but their application to
clinical practice in this situation is still limited. In part, the
failure to prescribe an ACE inhibitor to a patient with left
ventricular systolic dysfunction is due to perceptions re-
garding their side effects, such as cough and renal dysfunc-
tion. Relatively few patients with left ventricular systolic
dysfunction and a serum creatinine $2 mg/dl receive an
ACE inhibitor in clinical practice. In this situation one
should consider an agent such as fosinopril, which is meta-
bolized by the liver as well as secreted by the kidney. In
patients with moderate renal dysfunction, fosinopril has
been well tolerated without an increase in serum creat-
inine. In patients who develope cough due to an ACE inhibi-
tor, consideration should be given to an angiotensin II type
1 receptor blocking agent, such as losartan. The relative
safety and ef~cacy of an ACE inhibitor compared with an
angiotensin II type 1 receptor blocking agent is being ex-
plored in a prospective randomized trial (Evaluation of
Losartan In The Elderly [ELITE]), as well as the safety and
pharmacological effectiveness of adding an angiotensin II
receptor antagonist to an ACE inhibitor (Randomized An-
giotensin receptor antagonists — ACE-inhibitor Study
[RAAS]). There may also be a role for the combination of an
aldosterone receptor antagonists and an ACE inhibitor in
patients with left ventricular systolic dysfunction. Once an
ACE inhibitor is administered to a patient with left ven-
tricular systolic dysfunction it should be continued inde~-
nitely. ACE inhibitors may be of value not only in prevent-
ing the progression of heart failure but also in reversing
endothelial dysfunction and preventing the development of
atherosclerosis and its consequences, such as myocardial
infarction.
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Angiotensin-converting enzyme (ACE) inhibitors
have been shown to be effective in reducing morbidity
and mortality in patients with chronic left ventricular
systolic dysfunction regardless of etiology, time from
onset of left ventricular dysfunction, gender, or age
[1–3]. They have also been shown to reduce mortality
in patients with left ventricular systolic dysfunction or
manifest congestive heart failure post infarction [4–9].
Recent studies suggest that patients with extensive
left ventricular systolic dysfunction (left ventricular
ejection fraction #40%), anterior myocardial infarc-
tion, or manifest congestive heart failure should be
started on an ACE inhibitor within the ~rst 24 hours of
the onset of infarction [6,7]. There is also evidence to
suggest that ACE inhibitors may play an important
role in patients with relatively uncomplicated small
infarcts when administered orally within the ~rst 24
hours postinfarction [6,7]. While the mechanism for the
bene~t in acute myocardial infarction with left ven-
tricular systolic dysfunction has been thought to be
due, in large part, prevention of left ventricular dilata-
tion and remodeling [10,11], recent evidence suggests
that administration within the ~rst 24 hours of the
onset of infarction may provide bene~t related to a
reduction in cardiac rupture and sudden cardiac death
independent of the effect on ventricular remodeling
[6,7,12].
Use of ACE Inhibitors
Although the evidence supporting the use of ACE in-
hibitors in patients with chronic left ventricular sys-
tolic dysfunction and postinfarction is based on ran-
domized studies of over 100,000 patients, it is of
interest that the use of these agents, at least until
recently, has been suboptimal. For example, it is esti-
mated that ,50% of patients with a diagnosis of heart
failure received an ACE inhibitor in the United States
[13]. While clinical adaptation of results from major
randomized trials has been noted to be relatively slow
[14], in part because of a time lag in dissemination of
information relating to these trials, a large part of the
reason for not using ACE inhibitors in heart failure
may relate to their perceived side effects or contrain-
dications.
In many of the major clinical trials, ACE inhibitors
were not administered if the serum creatinine was $2
mg/dl. It is well recognized that ACE inhibitors, by
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altering glomerular perfusion, may result in a decrease
in creatinine clearance, and an increase in serum creat-
inine and potassium, occasionally to potentially dan-
gerous levels. While it is reasonable to be cautious
when considering the use of an ACE inhibitor in a
patient with compromised renal function, it should be
recognized that failure to administer them may expose
the patient to an increased risk of recurrent heart fail-
ure or death. Rather than considering an elevated se-
rum creatinine of 2–5 as an absolute contraindication,
it is reasonable to administer an ACE inhibitor to these
patients with careful monitoring of serum creatinine
and potassium. While some of these patients will dem-
onstrate an increase in serum creatinine and potas-
sium, many, however, will be able to tolerate the drug.
As an alternative, or in those who demonstrate an
increase in serum creatinine after a trial of an ACE
inhibitor, the use of fosinopril should be considered. In
contrast to most ACE inhibitors, fosinopril is elimi-
nated via a dual pathway, through the kidney and the
liver [15]. In patients with moderate renal dysfunction,
fosinopril has been shown to be relatively well toler-
ated, with little increase in serum creatinine or potas-
sium. However, not all patients will tolerate its admini-
stration, and serum creatinine and potassium need to
be carefully monitored, at least for the ~rst several
days and weeks.
Cough
Another clinical concern with the use of ACE inhibi-
tors in patients with heart failure relates to the occur-
rence of cough. The incidence of cough after an ACE
inhibitor appears to be greatest in the elderly and in
Asian patients, occasionally reaching an incidence of
10–20% in these groups [16]. Before discontinuing an
ACE inhibitor in a patient with a cough, one should
consider whether the cough is due to heart failure,
other causes, or the ACE inhibitor itself. In random-
ized trials such as the SOLVD trial [2], cough was
relatively common in patients randomized to placebo.
Our strategy is to discontinue the ACE inhibitor and
to re-evaluate the patient after 1–2 weeks. In those in
whom the cough persists despite the withdrawal of the
ACE inhibitor, the cough is likely to be due to heart
failure or other causes and the ACE inhibitor should be
readministered. In those who become free of cough, the
cough is likely to be due to the ACE inhibitor. In this
situation it is often worthwhile to discuss the situation
with the patient. Some patients, after reviewing the
survival advantages of an ACE inhibitor, may decide
that the cough, although onerous, is tolerable, while in
others the cough may interfere with the quality of life
and should be discontinued. In these patients consid-
eration should be given to the use of an angiotensin II
type 1 receptor blocking agent, such as losartan. While
there is of yet only limited experience with the use of
angiotensin II type 1 receptor-blocking agents in pa-
tients with heart failure, they have been shown to be
relatively well tolerated and to improve exercise toler-
ance [18]. They are unlikely to provoke cough because
the cough has been associated with ACE inhibitor-in-
duced bradykinin accumulation. Angiotensin II type 1
receptor antagonists block most, if not all, of the detri-
mental effects of angiotensin II but do not cause an
increase in bradykinin accumulation because the
angiotensin-converting enzyme that is responsible for
degrading bradykinin is not inhibited [18].
Angiotensin II Receptor Blockade in
Heart Failure and Bradykinin
While it is reasonable to postulate that blockade of
angiotensin II type 1 receptors will be bene~cial in
patients with heart failure, it should be emphasized
that there is experimental evidence suggesting that at
least part of the bene~cial effects of ACE inhibitors in
heart failure and postinfarction may be due to accumu-
lation of bradykinin rather than to inhibition of
angiotensin II formation. For example, in animals
ACE inhibitors have been shown to reduce infarct size
after experimental coronary artery occlusion [19]. This
bene~cial effect, however, is negated by the admini-
stration of the bradykinin antagonist HOE140 [19]. It
should be pointed out, however, that there is great
species differences in bradykinin accumulation and ef-
fect after ACE inhibition. Furthermore, bradykinin is
an endothelial-mediated vasodilator. In patients with
heart failure and in those with ischemic heart disease,
endothelial dysfunction is often present [20–22] and
bradykinin may lose its vasodilator effect [23]. Thus,
the relative role of bradykinin accumulation in the
bene~cial effects of ACE inhibitors and the relatively
ef~cacy and safety of an angiotensin II type 1 receptor
antagonist in comparison with an ACE inhibitor, are
uncertain. Further information in this regard should
be forthcoming from the Evaluation of Losartan In The
Elderly trial (ELITE), which is comparing the safety
and ef~cacy of the angiotensin II type 1 receptor an-
tagonist losartan with the ACE inhibitor captopril in
over 700 patients with heart failure. The rationale and
design of this study have been described previously
[24]. An exploration of the relative ef~cacy and safety
of an angiotensin II type 1 receptor antagonist com-
pared with an ACE inhibitor has important implica-
tions for the therapy of patients with left ventricular
dysfunction.
Residual Mortality in ACE-Inhibitor
Trials and Angiotensin II Escape
Although patients on an ACE inhibitor have been
shown to have a decrease in morbidity and mortality in
comparison with patients maintained on digoxin, diu-
retics, and placebo, it should be emphasized that there
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is still a relatively high incidence of morbidity and mor-
tality despite currently recommended target doses of
an ACE inhibitor, such as enalapril 10 mg bid. For
example, in the SOLVD trial there was a 47.7% inci-
dence of recurrent heart failure or death in patients
randomized to 10 mg enalapril bid [2]. There are sev-
eral possible explanations for this residual morbidity
and mortality, including the fact that other neurohor-
mones or factors are likely to be of pathophysiologic
importance in heart failure, such as norepinephrine,
endothelin, and vasopressin, and it should not be ex-
pected that even optimal blockade of the renin-
angiotensin-aldosterone system would eliminate all
morbidity and mortality.
It is likely, however, that while it is unreasonable to
expect that optimal blockade of the RAAS would com-
pletely eliminate all morbidity and mortality in pa-
tients with left ventricular systolic dysfunction post-in-
farction, current strategies are not optimal and further
bene~t may be achieved by optimal blockade of the
RAAS. For example, it has been shown that patients
who show evidence of progressive heart failure despite
therapy with enalapril have elevated angiotensin II
levels [25]. This elevation or “escape” of angiotensin II
production despite doses of enalapril that are thought
to be effective in blocking serum ACE could be caused
by inadequate absorption of enalapril in patients with
heart failure or failure to achieve optimal dosing.
Although 10 mg bid of enalapril has been shown to
be effective in reducing morbidity and mortality in the
SOLVD Trial [2], it is not certain that this is the optimal
dose, and others have suggested that even higher
doses of enalapril are necessary to optimally suppress
angiotensin II formation [26]. It is also possible that
angiotensin II may be produced by non-ACE as well as
ACE-dependent mechanisms [27]. While ACE inhibi-
tors may be effective in blocking ACE-dependent
angiotensin II formation, they would not be expected
to block non-ACE-dependent angiotensin II formation.
If non-ACE-dependent angiotensin II formation is of
pathophysiologic importance in heart failure or postin-
farction, it would be expected that an angiotensin II
type 1 receptor blocker might in fact be more effective
than an ACE inhibitor under certain circumstances.
Only direct comparative studies in humans will provide
the answer to the question of the relative safety and
ef~cacy of an angiotensin II type 1 receptor antagonist
versus an ACE inhibitor.
Combination of ACE Inhibitors and
Angiotensin II Type I Blocking Agents
Since it is possible that at least some of the bene~cial
effects of ACE inhibitors are due to bradykinin accu-
mulation and that either because of suboptimal dosing
or non-ACE-dependent angiotensin II formation,
angiotensin II is not optimally suppressed, we have
also begun to explore the strategy of combining an
ACE inhibitor and an angiotensin II type 1 receptor
blocking agent. The Randomized Angiotensin receptor
Antagonist — ACE-inhibitor Study (RAAS) is explor-
ing the hypothesis that the combination of an angioten-
sin II type 1 receptor antagonist, losartan, and an ACE
inhibitor, enalapril, is more effective than enalapril
alone when used at target doses, 10 mg bid, or at even
higher doses, such as 20 mg bid. Use of this combina-
tion should allow ACE-inhibitor-induced bradykinin
accumulation as well as further suppression of angio-
tensin II, either because of receptor blockade of resid-
ual ACE-dependent angiotensin II formation and/or
non-ACE-dependent angiotensin II formation. The
RAAS Pilot Study is exploring the safety of this com-
bination as well as its relative ef~cacy in suppressing
neurohormones, including norepinephrine, aldoster-
one, and atrial natriuretic peptide at rest and during
exercise.
ACE Inhibition and Aldosterone
Another potential problem with our current use of
ACE inhibitors is that fact that aldosterone is not com-
pletely suppressed with currently used doses and may
escape despite complete inhibition of plasma ACE [28].
Although aldosterone production is in large part de-
pendent upon angiotensin II production, there are
other mechanisms controlling aldosterone production,
including ACTH, serum potassium, and atrial natri-
uretic factor. The evidence for an “escape” of aldos-
terone production despite ACE inhibition, and its clini-
cal implications have been recently reviewed [29]. To
explore the possibility of aldosterone escape in pa-
tients with heart failure, the Randomized ALdactone
Evaluation Study (RALES) has been initiated to ex-
plore the safety and ef~cacy of spironolactone when
administered in conjunction with an ACE inhibitor in
patients with left ventricular systolic dysfunction and
heart failure. The RALES Pilot Study [30] explored
the safety of placebo and of spironolactone at 12.5, 25,
50, and 75 mg daily when administered in conjunction
with an ACE inhibitor. This study showed spironolac-
tone in doses of 12.5–25 mg daily to be safe and phar-
macologically effective, as evidenced by a signi~cant
decrease in serum atrial natriuretic peptide levels. The
results of this study were used to design the RALES
Mortality Trial, which is currently exploring the effect
of spironolactone 25 mg daily to reduce total mortality
in patients with severe heart failure maintained on an
ACE inhibitor or in patients intolerant of an ACE in-
hibitor.
Duration of Treatment 
with ACE Inhibitors
Another problem with the use of ACE inhibitors is how
long they should be administered. In patients with per-
sistent left ventricular systolic dysfunction (LVEF
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#40%), it seems reasonable to continue ACE-inhibitor
therapy lifelong because withdrawal from ACE inhibi-
tor therapy results in ventricular dilatation and recur-
rent signs of heart failure [31]. In patients with chronic
heart failure or postinfarction with an improvement in
ejection fraction to .40%, it might be reasonable to
consider withdrawing ACE inhibitor therapy after 4–6
weeks because there is no evidence that patients with
relatively well-preserved ventricular function (EF
.40%) undergo long-term ventricular remodeling or
progressive ventricular dilation. On the other hand, a
case can be made for lifelong therapy, even in these
patients. In the SOLVD [32] and SAVE [33] studies,
ACE inhibitors were associated with a signi~cant re-
duction in the incidence of ischemic events. There is
increasing experimental evidence suggesting that ACE
inhibitors may reverse endothelial dysfunction and pre-
vent atherosclerosis, plaque rupture, and thrombosis
[34]. Of importance in the potential bene~t of ACE in-
hibitors in preventing myocardial infarction and is-
chemic events is the ~nding that angiotensin II can
cause the oxidation of low-density lipoprotein choles-
terol [35]. Oxidation of low-density lipoprotein cho-
lesterol and free radical formation have important det-
rimental effects on the development of atherosclerosis
and ventricular function. ACE inhibitors, by prevent-
ing angiotensin II-induced oxidation of LDL-C, oxygen
free radical production, cytokine production, endothe-
lial dysfunction, endothelin release, platelet activation,
and plasminogen activator inhibitor release, could have
an important effect on the prognosis of coronary and
other vascular disease. The ~rst test of this hypothesis
is being explored in the QUinipril Ischemic Event Trial
(QUIET), the background and design of which have
been previously described [36]. The fact that ACE in-
hibitors prevent the oxidation of LDL-C, and reverse
endothelial dysfunction and experimental atheroscle-
rosis, suggests that they may act syngenetically or addi-
tively with cholesterol-lowering strategies, which also
prevent oxidation of LDL-C, endothelial dysfunction,
atherosclerosis, endothelin, and plasminogen activator
inhibitor release. Should QUIET demonstrate a signi-
~cant effect of the ACE inhibitor quinipril in reducing
ischemic events in patients without left ventricular sys-
tolic dysfunction, ACE inhibitors might be indicated for
the secondary prevention of ischemic heart disease and
would likely be administered lifelong in patients with




It also likely that ACE inhibitors act syngenetically or
additively with beta-adrenergic receptor blocking
agents. Angiotensin II causes the release of norepi-
nephrine [37], while ACE inhibitors, at least in part,
prevent norepinephrine release as well as free radical
formation [38]. The recent demonstration of the effec-
tiveness of carvedilol in patients with heart failure
maintained on an ACE inhibitor [39], as well as previous
studies demonstrating the effect of ACE inhibitors in
patients maintained on a beta-adrenergic receptor
blocking agent [4], suggest a bene~cial interaction. Pre-
vention of oxygen free radical formation by ACE inhibi-
tors and/or an increase in antioxidant defense mecha-
nisms may be of importance in their bene~cial effect in
situations in which norepinephrine release is thought to
be pathophysiologically important, such as severe heart
failure, because it has recently been shown that the
oxidation products of catecholamines, amniochromes,
are more predictive of mortality on multivariant analy-
sis than catecholamine levels themselves [40]. The
bene~cial effect of carvedilol in patients with heart fail-
ure treated with an ACE inhibitor may also be ex-
plained in part by a bene~cial synergistic or additive
effect of carvedilol, which has antioxidant properties
[41], in conjunction with the effects of ACE inhibitors on
oxygen free radical formation and increasing antioxi-
dant defense mechanisms [38,42]. Although this hy-
pothesis requires further prospective testing, it is likely
that oxygen free radical production is of critical impor-
tance in the pathophysiology of heart failure, including
the tendency to develop apoptosis, progressive myocar-
dial cell death, and sudden cardiac death.
Conclusions
Despite considerable experience with the use of ACE
inhibitors in the treatment of both chronic systolic left
ventricular dysfunction and postinfarction heart fail-
ure there remain many unanswered questions and op-
portunities for further reducing morbidity and mortal-
ity in these patients by optimizing the blockade of the
RAAS and by exploring synergistic and/or comple-
mentary adjunctive strategies.
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